Unlock Full Company Report
Access verified contacts, investors & buying signals.
Recently Funded|Amount: USD 1.9M|Industry: Biotechnology Research
OKYO Pharma Secures $1.9M to Accelerate Next-Gen GPCR Therapies for Ocular Inflammation and Chronic Pain Relief
OKYO Pharma

View Full Report
Includes contacts, investors & buying signals
OKYO Pharma has recently secured 1,900,000 in funding, marking an exciting new chapter in the company’s mission to revolutionize the treatment of ocular inflammatory conditions and chronic pain. This fresh capital injection will be instrumental in advancing innovative therapies, including a novel class of membrane-anchored Chemerin receptor GPCR agonists designed to target inflammatory pathways, offering new hope for patients suffering from dry eye syndrome, uveitis, and allergic conjunctivitis. Additionally, the company is developing an agonist for MAS-Related G Protein-Coupled Receptor (MRGPR) that serves as a non-opioid analgesic, aimed at delivering effective relief for both ocular and chronic pain through novel topical and nasal formulations. By channeling these funds into accelerating preclinical and clinical trials, OKYO Pharma is poised to expedite the development and regulatory approval process for these groundbreaking treatments. The robust funding round not only reinforces investor confidence in the company's innovative approach but also underscores the urgent need for safer, more effective therapeutic options in eye care and pain management. With its strong focus on precision medicine and addressing unmet clinical needs, OKYO Pharma is committed to creating therapies that improve patient outcomes and quality of life. As the company embarks on this ambitious growth phase, it stands at the forefront of medical innovation, ready to transform current treatment paradigms and offer significant advancements in healthcare solutions for millions worldwide.
Buying Signals & Intent
Our AI suggests OKYO Pharma may be interested in solutions related to:
- Drug Development
- Clinical Trials
- Investments in Healthcare
- Research and Development
- Innovative Therapeutics
Sell these products?
Unlock full report to find contacts.
Investors
Unlock Investor Data
See who invested in OKYO Pharma and potentially find related investment contacts.
Unlock Premium AccessKey Decision Makers
Unlock Verified Contacts
Get direct email addresses and phone numbers for key decision makers at OKYO Pharma.
Unlock Contacts Now